Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095160 · ClinicalTrials.gov registry record · Phase 1
Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00095160 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 42 participants.
The verdict
NCT00095160, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
Study 1493-852A is a phase 1 study with the primary objective of determining safety and the highest tolerated dose of an experimental immune response modifier administered intravenously to patients with solid organ tumors not responsive to currently available treatments. The secondary objective of the study is to monitor the tumor response to this form of treatment.
Interventions
- DRUG 852A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095160
The ClinicalTrials.gov registry entry for NCT00095160 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 852A is the first listed.
NCT00095160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095160 about?
NCT00095160 is a clinical study titled "Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors". Study 1493-852A is a phase 1 study with the primary objective of determining safety and the highest tolerated dose of an experimental immune response modifier administered intravenously to patients with solid organ tumors not responsive to currently available treatments. The secondary objective of t...
What is the current status of trial NCT00095160?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2003-10. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00095160?
The interventions under investigation include: 852A (DRUG).
Who is sponsoring clinical trial NCT00095160?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.